Eduardo Lacson1, Weiling Wang2, Lin Ma3, Jutta Passlick-Deetjen4. 1. Fresenius Medical Care North America, Waltham, MA. Electronic address: nephdoc92@gmail.com. 2. Alcon Laboratories, Fort Worth, TX. 3. Fresenius Medical Care North America, Waltham, MA. 4. Department of Nephrology, University of Duesseldorf, Duesseldorf, Germany.
Abstract
BACKGROUND: Low serum magnesium levels in patients with kidney disease have been linked to increased mortality. This study investigated whether similar associations existed in maintenance hemodialysis (HD) patients. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: All Fresenius Medical Care North America in-center HD patients with available serum magnesium measurements were studied. The initial exploratory study in 21,534 HD patients evaluated associations among serum magnesium level, dialysate magnesium concentration, and mortality from April 2007 through June 2008. The follow-up study in 27,544 HD patients evaluated associations between serum magnesium levels and mortality over 1 year (January through December 2008). PREDICTORS: The primary predictor was serum magnesium level, with adjustment for case-mix (age, sex, race, diabetes, and dialysis vintage and additionally for follow-up study: body surface area and vascular access) and laboratory variables (albumin, hemoglobin, phosphorus, equilibrated Kt/V, potassium, calcium, and intact parathyroid hormone values). OUTCOME: Primary outcome variable was 1-year mortality risk, evaluated using Cox proportional hazards models. RESULTS: Among 21,534 HD patients in the exploratory study, there were 3,682 deaths. Higher dialysate magnesium level was associated with higher serum magnesium level (R=0.22; P<0.001). Patients with the lowest serum magnesium levels (<1.30 mEq/L) were at highest risk for death (HR, 1.63; 95% CI, 1.30-1.96; reference serum magnesium, 1.60-<1.90 mEq/L). Among 27,544 HD patients in the follow-up study, there were 4,531 deaths. In Cox proportional hazards models, there was a linear decline in death risk from the lowest to the highest serum magnesium category, with the best survival at serum magnesium levels ≥ 2.50 mEq/L (HR, 0.68; 95% CI, 0.56-0.82). However, risk estimates were attenuated with case-mix and lab adjustment. This pattern was consistent within diabetes subgroups and for cardiovascular or noncardiovascular causes of death. LIMITATIONS: Observational study with cross-sectional serum magnesium measurements and no information for oral magnesium intake. CONCLUSIONS: Elevated serum magnesium levels > 2.10 mEq/L were associated with better survival than low serum magnesium levels < 1.30 mEq/L in HD patients. Prospective studies may determine whether manipulation of low serum magnesium levels affects survival.
BACKGROUND: Low serum magnesium levels in patients with kidney disease have been linked to increased mortality. This study investigated whether similar associations existed in maintenance hemodialysis (HD) patients. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: All Fresenius Medical Care North America in-center HDpatients with available serum magnesium measurements were studied. The initial exploratory study in 21,534 HDpatients evaluated associations among serum magnesium level, dialysate magnesium concentration, and mortality from April 2007 through June 2008. The follow-up study in 27,544 HDpatients evaluated associations between serum magnesium levels and mortality over 1 year (January through December 2008). PREDICTORS: The primary predictor was serum magnesium level, with adjustment for case-mix (age, sex, race, diabetes, and dialysis vintage and additionally for follow-up study: body surface area and vascular access) and laboratory variables (albumin, hemoglobin, phosphorus, equilibrated Kt/V, potassium, calcium, and intact parathyroid hormone values). OUTCOME: Primary outcome variable was 1-year mortality risk, evaluated using Cox proportional hazards models. RESULTS: Among 21,534 HDpatients in the exploratory study, there were 3,682 deaths. Higher dialysate magnesium level was associated with higher serum magnesium level (R=0.22; P<0.001). Patients with the lowest serum magnesium levels (<1.30 mEq/L) were at highest risk for death (HR, 1.63; 95% CI, 1.30-1.96; reference serum magnesium, 1.60-<1.90 mEq/L). Among 27,544 HDpatients in the follow-up study, there were 4,531 deaths. In Cox proportional hazards models, there was a linear decline in death risk from the lowest to the highest serum magnesium category, with the best survival at serum magnesium levels ≥ 2.50 mEq/L (HR, 0.68; 95% CI, 0.56-0.82). However, risk estimates were attenuated with case-mix and lab adjustment. This pattern was consistent within diabetes subgroups and for cardiovascular or noncardiovascular causes of death. LIMITATIONS: Observational study with cross-sectional serum magnesium measurements and no information for oral magnesium intake. CONCLUSIONS: Elevated serum magnesium levels > 2.10 mEq/L were associated with better survival than low serum magnesium levels < 1.30 mEq/L in HDpatients. Prospective studies may determine whether manipulation of low serum magnesium levels affects survival.
Authors: Casey M Rebholz; Adrienne Tin; Yang Liu; Marie Fanelli Kuczmarski; Michele K Evans; Alan B Zonderman; Deidra C Crews Journal: Am J Nephrol Date: 2016-10-22 Impact factor: 3.754
Authors: Silvia Ferrè; Xilong Li; Beverley Adams-Huet; Naim M Maalouf; Khashayar Sakhaee; Robert D Toto; Orson W Moe; Javier A Neyra Journal: J Investig Med Date: 2019-03-02 Impact factor: 2.895
Authors: Silvia Ferrè; Xilong Li; Beverley Adams-Huet; Naim M Maalouf; Khashayar Sakhaee; Robert D Toto; Orson W Moe; Javier A Neyra Journal: Nephrol Dial Transplant Date: 2018-08-01 Impact factor: 5.992